Neuphoria Therapeutics Inc.
NASDAQNeuphoria Therapeutics heads into its May 18 earnings report freshly downgraded and under fresh selling pressure, with the analyst who once championed the stock now standing aside. The most consequential development heading into the print is the timing of Thursday's analyst action. HC Wainwright's Joseph Pantginis — the sole covering analyst — downgraded NEUP to Neutral from Buy on…
NEUP short interest surges 38.3% in one week to 0.83% of float, with utilization jumping to 82.2% — highest level in recent sessions.
Snapshot as of 16 May 2026
Neuphoria Therapeutics heads into its May 18 earnings report freshly downgraded and under fresh selling pressure, with the analyst who once championed the stock now standing aside. The most consequential development…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NEUP — free to start on ORTEX.
Sign up for free →Open NEUP on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live NEUP data →